IQWiG reverses on Stivarga, supports melanoma combos

The German Institute for Quality and Efficiency in Health Care reversed an earlier assessment of Stivarga regorafenib from Bayer AG (Xetra:BAYN), saying that the drug's benefit "is no longer proven" in treating metastatic colorectal cancer (mCRC).

IQWiG found a marginal benefit for Stivarga over best supportive care in 2014, but noted that patients also experienced side effects including fatigue and diarrhea more frequently. In a new assessment that examined quality of life data, IQWiG said "the negative effects now outweighed the advantage in all-cause mortality." ...